Holen Sie sich die Stockscreener-App
2.39
7.00%
-0.18
Schlusskurs vom Vortag:
$2.57
Offen:
$2.56
24-Stunden-Volumen:
164.58K
Relative Volume:
0.97
Marktkapitalisierung:
$16.88M
Einnahmen:
$2.90M
Nettoeinkommen (Verlust:
$87.91M
KGV:
0.1531
EPS:
15.6103
Netto-Cashflow:
$-26.93M
1W Leistung:
-8.08%
1M Leistung:
+6.22%
6M Leistung:
+68.31%
1J Leistung:
-52.11%
1-Tages-Spanne:
$2.35
$2.6701
1-Wochen-Bereich:
$2.35
$3.10
52-Wochen-Spanne:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Vergleichen Sie TRAW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.39 | 18.31M | 2.90M | 87.91M | -26.93M | 15.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Can Traws Pharma Inc. (0T20) stock sustain institutional flowsWeekly Profit Report & AI Powered Market Trend Analysis - newser.com
Why ETFs are accumulating Traws Pharma Inc. (0T20) stockJuly 2025 Trends & Risk Controlled Daily Trade Plans - newser.com
Live market analysis of Traws Pharma Inc.July 2025 EndofMonth & Real-Time Stock Movement Alerts - newser.com
Visualizing Traws Pharma Inc. stock with heatmapsJobs Report & High Accuracy Trade Alerts - newser.com
Using RSI to spot recovery in Traws Pharma Inc.Weekly Risk Summary & Step-by-Step Trade Execution Guides - newser.com
Why Traws Pharma Inc. is moving todayTrade Volume Summary & Verified Chart Pattern Trade Signals - newser.com
Will Traws Pharma Inc. (0T20) stock extend growth story2025 Support & Resistance & Low Risk High Reward Trade Ideas - newser.com
Is Traws Pharma Inc. (0T20) stock supported by free cash flowPrice Action & Daily Stock Momentum Reports - newser.com
Technical signs of recovery in Traws Pharma Inc.2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
Measuring Traws Pharma Inc.’s beta against major indicesWatch List & Fast Gaining Stock Strategy Reports - newser.com
How Traws Pharma Inc. stock reacts to inflationary pressures2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
What the charts say about Traws Pharma Inc. todayExit Point & Stepwise Trade Signal Guides - newser.com
Is Traws Pharma Inc. (0T20) stock testing key supportJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
What technical models suggest about Traws Pharma Inc.’s comebackEarnings Growth Report & Risk Controlled Daily Plans - newser.com
Price action breakdown for Traws Pharma Inc.July 2025 Weekly Recap & Fast Entry and Exit Trade Plans - newser.com
Is Traws Pharma Inc. forming a reversal patternMarket Activity Report & High Accuracy Investment Signals - newser.com
Traws Pharma (NASDAQ:TRAW) Upgraded at Wall Street Zen - Defense World
Tick level data insight on Traws Pharma Inc. volatilityPortfolio Gains Summary & Breakout Confirmation Alerts - newser.com
Is a relief rally coming for Traws Pharma Inc. holdersWeekly Trend Recap & Comprehensive Market Scan Insights - newser.com
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - MarketScreener
2025-10-30 | ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials | NDAQ:TRAW | Press Release - Stockhouse
Advanced analytics toolkit walkthrough for Traws Pharma Inc.Earnings Risk Report & Fast Gain Stock Tips - newser.com
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):